<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36987601</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Health inequalities and systemic lupus erythematosus: a global challenge.</ArticleTitle><Pagination><StartPage>i1</StartPage><EndPage>i3</EndPage><MedlinePgn>i1-i3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/kead058</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Ian N</ForeName><Initials>IN</Initials><Identifier Source="ORCID">0000-0003-3047-500X</Identifier><AffiliationInfo><Affiliation>Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36987601</ArticleId><ArticleId IdType="pmc">PMC10050936</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kead058</ArticleId><ArticleId IdType="pii">7087224</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee YH, Choi SJ, Ji JD, Song GG.. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016;25:727&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">26811368</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber MRW, Drenkard C, Falasinnu T. et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021;17:515&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982275</ArticleId><ArticleId IdType="pubmed">34345022</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Clarke AM, Bruce IN, Symmons DP.. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum 2006;54:2963&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16947632</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Hiraki LT, Liu J. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000&#x2013;2004. Arthritis Rheum 2013;65:753&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733212</ArticleId><ArticleId IdType="pubmed">23203603</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G, Lenz O, Pardo V. et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16598205</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Liang M, Duan J. et al. Age differences in secular trends in black&#x2013;white disparities in mortality from systemic lupus erythematosus among women in the United States from 1988 to 2017. Lupus 2021;30:715&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">33535903</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy EM, Sutton E, Nesbit S. et al.; British Isles Lupus Assessment Group Biologics Register. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford) 2018;57:470&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5850287</ArticleId><ArticleId IdType="pubmed">29216396</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcn GS, McGwin G Jr, Bastian HM. et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001;45:191&#x2013;202. Erratum in: Arthritis Rheum 2001;45:306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11324784</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschken CA, Katz SJ, Silverman E. et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol 2009;36:1200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19369456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasitanon N, Louthrenoo W, Sukitawut W, Vichainun R.. Causes of death and prognostic factors in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2002;20:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12403192</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber MRW, Falasinnu T, Ramsey-Goldman R, Clarke AE.. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology (Oxford) 2023;62:i4&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050933</ArticleId><ArticleId IdType="pubmed">36987602</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JN, Drenkard C, Lim SS.. The impact of social determinants of health on the presentation, management, and outcomes of systemic lupus erythematosus. Rheumatology (Oxford) 2023;62:i10&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050938</ArticleId><ArticleId IdType="pubmed">36987604</ArticleId></ArticleIdList></Reference><Reference><Citation>Demkova K, Morris DL, Vyse TJ.. Genetics of SLE: does this explain susceptibility and severity across racial groups? Rheumatology (Oxford) 2023;62:i15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050932</ArticleId><ArticleId IdType="pubmed">36583554</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Li Z.. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology (Oxford) 2023;62:i22&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050939</ArticleId><ArticleId IdType="pubmed">36987605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Pinto C, Etchegaray-Morales I, Ugarte-Gil MF.. Improving access to SLE therapies in low and middle-income countries (LMICs). Rheumatology (Oxford) 2023;62:i30&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050935</ArticleId><ArticleId IdType="pubmed">36987603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>